The metabolic-epigenetic axis represents a critical bridge between cellular energy status and gene expression regulation in neurodegenerative diseases. Metabolites serve as cofactors for epigenetic enzymes, creating a direct mechanistic link between metabolic dysfunction and epigenetic dysregulation that drives disease progression.
Epigenetic modifications (DNA methylation, histone modifications, chromatin remodeling) require metabolic intermediates as cofactors. Changes in cellular metabolism alter the availability of these cofactors, thereby modulating epigenetic enzyme activity and gene expression patterns. This bidirectional relationship creates feedback loops that amplify pathological cascades in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and frontotemporal dementia (FTD)[@kopp2023metabolic].
The metabolic-epigenetic axis encompasses several key metabolic pathways that influence epigenetic regulation:
α-Ketoglutarate (α-KG), a key intermediate in the tricarboxylic acid (TCA) cycle, serves as the essential cofactor for JmjC-domain-containing histone demethylases (JHDMs)[@cheng2019alpha]. The α-KG/succinate ratio directly determines demethylase activity:
In neurodegeneration, mitochondrial dysfunction reduces α-KG production while accumulating succinate (an α-KG antagonist), shifting the epigenetic landscape toward a repressive state[@tsaikou2022alpha].
The one-carbon metabolism pathway provides SAM, the universal methyl donor for DNA and histone methylation. This pathway links folate and homocysteine metabolism to epigenetic regulation:
Key enzymes in one-carbon metabolism:
Polymorphisms in MTHFR (C677T) are associated with increased AD risk, likely through homocysteine elevation and subsequent SAM depletion[@kim2023mthfr].
Sirtuins (SIRT1-7) are NAD+-dependent deacetylases that link cellular energy status to epigenetic regulation. SIRT1 primarily targets histones (H3K9, H3K14, H4K16) and transcription factors[@bonda2011sirtuin]:
| Sirtuin | Localization | Primary Targets | Role in Neurodegeneration |
|---|---|---|---|
| SIRT1 | Nucleus | H3K9ac, H4K16ac, p53, PGC-1α | Neuroprotective, promotes autophagy |
| SIRT2 | Cytoplasm | H4K16ac, α-tubulin | Links metabolism to α-syn aggregation |
| SIRT3 | Mitochondria | SOD2, IDH2 | Antioxidant defense |
| SIRT5 | Mitochondria | CPS1, GLUD1 | Urea cycle, glutamate metabolism |
| SIRT6 | Nucleus | H3K9ac, H3K56ac | DNA repair, stress response |
NAD+ depletion in aging and neurodegeneration reduces sirtuin activity, contributing to epigenetic dysregulation and mitochondrial dysfunction[@lautrup2019nad].
A recent breakthrough in epigenetics is the discovery of lysine lactylation (Kla) as a new histone modification[@zhang2019lactate]. Lactate serves as a substrate for lactylation, directly linking glycolytic activity to epigenetic regulation:
Lactylation appears to promote gene activation, contrasting with typical lactate-associated metabolic stress. This modification may represent a compensatory mechanism or a pathological driver depending on context.
β-Hydroxybutyrate (βHB), a ketone body produced during fasting or ketogenic diets, influences epigenetic regulation through multiple mechanisms[@newman2017beta]:
The ketogenic diet's purported benefits in epilepsy and potentially in neurodegeneration may operate partly through this metabolic-epigenetic mechanism.
In AD, the metabolic-epigenetic axis manifests through multiple mechanisms:
| Metabolic Change | Epigenetic Consequence | Pathological Impact |
|---|---|---|
| ↓ NAD+ | ↓ SIRT1 activity | Reduced autophagy, increased p53 acetylation |
| ↓ α-KG | ↓ JmjC demethylase activity | Repressed neuroprotective genes |
| ↓ SAM | ↑ DNA hypermethylation | Tau pathology amplification |
| ↑ Homocysteine | ↓ MTHFR activity | Cardiovascular contribution |
| ↑ Lactate | ↑ H3K18 lactylation | Microglial activation genes |
The APOE4 allele exacerbates metabolic dysfunction, reducing NAD+ levels and impairing SIRT1-mediated neuroprotection[@cheng2016apoe].
In PD, metabolic-epigenetic alterations connect mitochondrial dysfunction to α-synuclein pathology:
SIRT2 has emerged as a particularly relevant epigenetic regulator in PD, with SIRT2 inhibitors showing protective effects in α-synuclein models[@gutierrez2020sirt2].
The C9orf72 hexanucleotide repeat expansion creates a unique metabolic-epigenetic burden:
SOD1 and FUS mutations similarly affect metabolic pathways that impinge on epigenetic regulation.
| Target | Therapeutic Strategy | Development Stage | Disease |
|---|---|---|---|
| NAD+ precursors | NR, NMN, NRPT | Phase I-II | AD, PD |
| α-KG derivatives | Dimethyl α-KG (DMKG) | Preclinical | AD, PD |
| SIRT1 activators | Resveratrol, SRT2104 | Phase II | AD |
| SIRT2 inhibitors | AGK2, Tenovin-6 | Preclinical | PD |
| HDAC inhibitors | Vorinostat, RGFP966 | Phase I-II | AD, ALS |
| Ketogenic agents | KetoCal, AC-1202 | Phase III | AD |
| SAM supplementation | SAMe | Clinical use | Depression (off-label) |
Several trials target the metabolic-epigenetic axis:
α-Ketoglutarate derivatives:
One-carbon metabolism modulators:
Lactate lactylation inhibitors:
| Target | Company | Pipeline | Investment | Evidence Score |
|---|---|---|---|---|
| NAD+ precursors | ChromaDex (NR), Life Biosciences (NMN) | Phase II | $150M+ | 8/10 |
| SIRT1 activators | Sirtris/GSK (resveratrol analogs) | Phase II | $720M (acquisition) | 6/10 |
| HDAC inhibitors | Nanotherapeutics, AC Immune | Phase I | $85M | 7/10 |
| Target | Company | Pipeline | Investment | Evidence Score |
|---|---|---|---|---|
| α-KG derivatives | Juvenis, Axial | Preclinical | $25M | 5/10 |
| Ketogenic agents | Cerevel, Nestle | Phase III | $200M+ | 7/10 |
| SAM supplementation | Various generic | Clinical use | Minimal | 4/10 |
| Target | Company | Pipeline | Investment | Evidence Score |
|---|---|---|---|---|
| Lactylation modulators | Academic | Preclinical | $10M | 3/10 |
| SIRT2 inhibitors | Unknown | Preclinical | $5M | 4/10 |
| One-carbon modulators | Academic | Preclinical | $8M | 4/10 |
The metabolic-epigenetic axis represents a shared mechanism across neurodegenerative diseases, with disease-specific manifestations: